Intravenous (IV) insulin therapy with subcutaneous (SC) insulin is the mainstay of treatment in management of Hyperglycemia in hospitalized patients and has shown to improve morbidity and reduce mortality rates in critically ill patients [7,8]. This evidence concerns the gene INS and Hyperglycemia.